Skip Navigation LinksHome > September 1995 - Volume 10 - Issue 1 > Photodynamic Therapy in AIDS-Related Cutaneous Kaposi's Sarc...
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology:
Original Articles: PDF Only

Photodynamic Therapy in AIDS-Related Cutaneous Kaposi's Sarcoma.

Hebeda, Konnie M.; Huizing, Manon T.; Brouwer, Patrick A.; van der Meulen, Freerk W.; Hulsebosch, Hendrik J.; Reiss, Peter; Oosting, J. (Hans); Veenhof, Cees H. N.; Bakker, Piet J. M.

Collapse Box


Summary: For evaluating the role of photodynamic therapy (PDT) in the local treatment of acquired immune deficiency syndrome (AIDS)-related cutaneous Kaposi's sarcoma (KS), nine treatments were performed in eight human immunodeficiency virus-positive homosexual men. The patients received 2 mg Photofrin/kg and either 120 J/cm2 (n = 5) or 70 J/cm2 (n = 4) laser light (630 nm). A total of 83 lesions were evaluable for response with a follow-up of 3-8 months. The overall response rates by patient for all treated lesions were 50-100% (120 J/cm2) and 83.3-90.3% (70 J/cm2), with a median duration of 3 months (range, 2-6 months). Tumors located at the head had higher response rates than those at the trunk or extremities (p = 0.005 and p = 0.015 respectively). The size of the KS showed a negative relationship with the probability of complete response (p = 0.047). Local and general side effects occurred, including pain, blisters, temperature increase, muscle stiffness, and severe edema. The cosmetic result was unsatisfactory because of a high prevalence of scars and long-lasting hyperpigmentation. Although the response rates of PDT are high, light doses of 70-120 J/cm2 cannot be recommended in the treatment of cutaneous KS in combination with 2 mg/kg Photofrin because of severe side effects and unsatisfactory cosmetic result.

(C) Lippincott-Raven Publishers.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.